SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company was founded by Eric Rothe on August 29, 2006 and is headquartered in Stafford, TX.

Greenwich LifeSciences Inc

Greenwich LifeSciences is trending due to positive preliminary analysis showing an 80% reduction in breast cancer recurrence, sparking excitement among investors. The community is actively discussing the potential for a short squeeze given the high short interest and low float, with some speculating on a buyout. Many express strong conviction in the company's financials and the potential of its breast cancer drug, while others debate the significance of the open-label data.

ARB IOT Group Ltd. is a holding company that engages in the provision of solutions for the integration of IoT systems and devices. It operates through the Internet of Things and Investment Holding and Others segments. The company was founded on March 1, 2022 and is headquartered in Singapore.

ARB IOT Group Ltd

ARBB is trending due to speculation around a potential short squeeze, driven by its low float and recent price action; the community is watching key breakout levels. Bullish sentiment is fueled by comparisons to other low-float runners, though some caution against potential volatility and the risk of dilution. Chatter also mentions potential news catalysts and a signed AI + blockchain deal.

nLIGHT, Inc. engages in the provision of semiconductor and fiber lasers for aerospace and defense, industrial, and microfabrication applications. It operates through the Laser Products and Advanced Development segments. The Laser Products segment designs, manufactures, and sells a range of semiconductor lasers and fiber lasers that are typically integrated into laser systems or manufacturing tools built by customers. The Advanced Development segment focuses on research, design, and prototyping of next-generation laser technologies, leveraging expertise in laser technology, development, beam control, and advanced optics. The company was founded by Scott H. Keeney, Mark DeVito, and Jason Farmer in June 2000 and is headquartered in Camas, WA.

nLIGHT Inc

LASR is trending as investors discuss its potential role in defense contracts, particularly the "Golden Dome" initiative. The community is weighing the company's technology and market position, with some suggesting it's undervalued, while others point to near-term risks. Some see parallels with other defense stocks, anticipating a potential breakout if contracts materialize.

The 401jk (just kidding) meme is a satirical punch in the gut in the face of the concept of retirement and also the 401k. The 401k total holdings are valued at around $12 trillion USD and it is the most popular retirement savings plan in the US. As time passes forevermore true retirement, or as we like to call it real freedom will only become much harder and harder for people to attain.  Through meme fueled laser focus and cyperphunk ideology the 401jK meme retirement fund token and community aim to point out the absurdities of how rigged our current system is, and how only insiders and those with power are starting the benefit from the increased centralization of cryptocurrency.........while also aiming to flip the $12 trillion USD 401k system to achieve freedom before our backs and knees are breaking.

401jK

401JK is trending as community members rally around its anti-establishment narrative, promoting it as an alternative to traditional retirement plans. Discussions highlight the project's strong holder base, upcoming staking features, and a vision that challenges the traditional finance system. Despite overall market volatility, community members express conviction in the project's long-term potential as a movement.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is trending as the community discusses its potential for further upside, fueled by Wedbush's bullish stance and speculation around robotaxi progress; some are pointing to insider selling and EV competition as reasons to be cautious. Community members are actively debating the stock's valuation, future prospects, and potential price targets. Technical analysis chatter is focused on key levels and chart patterns to determine likely direction.

ServiceNow, Inc. engages in the provision of an end-to-end workflow automation platform for digital businesses. Its Now Platform is a cloud-based solution embedded with artificial intelligence (AI) and machine learning (ML). The company was founded by Frederic B. Luddy in June 2004 and is headquartered in Santa Clara, CA.

ServiceNow Inc

ServiceNow is trending amid talks of acquiring cybersecurity firm Armis for a potential $7 billion, which would be its largest deal yet, as it looks to bolster its security offerings. While some analysts are adjusting their ratings, the community is weighing the potential benefits of strengthening its portfolio in the connected device (IoT, OT, IT) security space. Community members also discussed the recent shareholder approval of a 5-for-1 stock split.

Kyverna Therapeutics, Inc. is a cell therapy clinical-stage biotechnology company, which engages in the provision of treatments and potential cures for serious autoimmune diseases. The company was founded in June 2018 and is headquartered in Emeryville, CA.

Kyverna Therapeutics Inc.

Kyverna Therapeutics is trending due to positive Phase 2 clinical trial results for its CAR-T therapy in stiff person syndrome, a rare autoimmune disease, driving significant premarket gains. Biotech traders and the community are discussing the potential FDA approval in 2026 and whether this niche market will affect long-term sales, while also highlighting analyst upgrades and buyout potential.

Opendoor Technologies, Inc. engages in the operation of buying, selling, and trading of residential properties online. The company was founded by Eric Wu on December 30, 2013, and is headquartered in Tempe, AZ.

Opendoor Technologies Inc

Opendoor ($OPEN) is trending amid leadership changes, including the appointment of Lucas Matheson as President and Christy Schwartz as CFO, fueling optimism about the company's future direction and potential growth phase. Community members are speculating on how these hires might impact strategy, particularly regarding tokenization and innovation, while also closely monitoring technical indicators for potential breakouts. Some traders express frustration and call for stronger communication from leadership as the stock navigates market fluctuations.

Immunome, Inc. is a biopharmaceutical company, which engages in the discovery and development of antibody therapeutics products. It also focuses on oncology and infectious disease areas. The company was founded by Scott K. Dessain and Gregory P. Licholai on March 2, 2006 and is headquartered in Bothell, WA.

Immunome Inc

IMNM is trending following positive Phase 3 trial results for its desmoid tumor treatment, varegacestat, sparking discussions about its potential market value compared to similar drugs. The community is focused on the drug's efficacy data and analyst ratings, particularly those highlighting improved chemistry over existing treatments. Some investors are considering securing profits amidst the volatility.

NuScale Power Corp. provides proprietary and innovative advanced small modular reactor (SMR) nuclear technology, with a mission to help power the global energy transition by delivering safe, scalable, and reliable carbon-free energy. Its products include VOYGR SMR Plants and Energy Exploration (E2) Centers. The company was founded by José N. Reyes in 2007 and is headquartered in Corvallis, OR.

NuScale Power Corporation - Ordinary Shares - Class A

NuScale Power Corp

NuScale Power is trending as investors weigh the company's future amid fluctuating market conditions and recent news. While some express long-term bullish sentiment due to the need for nuclear energy to power AI and data centers, others are concerned about share dilution and potential stake sales. The community is closely watching upcoming votes on share increases and monitoring for new contracts.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Alvotech Investor News: Rosen Law Firm Encourages Alvotech Investors to Inquire About Securities Class Action Investigation - ALVO

Alvotech Investor News: Rosen Law Firm Encourages Alvotech Investors to Inquire About Securities Class Action Investigation - ALVO Alvotech Investor News: Rosen Law Firm Encourages Alvotech Investors...

Alvotech (NASDAQ:ALVO) Shares Gap Down - Here's Why

Alvotech (NASDAQ:ALVO) Shares Gap Down - Here's What Happened...

Rosen Law Firm Encourages Alvotech Investors to Inquire About Securities Class Action Investigation - ALVO

Rosen Law Firm Encourages Alvotech Investors to Inquire About Securities Class Action Investigation - ALVO Rosen Law Firm Encourages Alvotech Investors to Inquire About Securities Class Action...

Alvotech (NASDAQ:ALVO) Stock Price Up 6.3% - Here's What Happened

Alvotech (NASDAQ:ALVO) Stock Price Up 6.3% - Time to Buy...

Oaktree Capital Management LP Trims Position in Alvotech $ALVO

Oaktree Capital Management LP trimmed its stake in Alvotech (NASDAQ:ALVO - Free Report) by 16.3% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm...

 New Strong Sell Stocks for Dec.5

ALVO, ADM and ASBFY have been added to the Zacks Rank #5 (Strong Sell) List on Dec. 5, 2025 

Rosen Law Firm Encourages Alvotech Investors to Inquire About Securities Class Action Investigation ALVO

Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Alvotech (NASDAQ: ALVO) resulting from allegations that...

New Strong Sell Stocks for Nov. 28

ALG, ALVO and CBRL have been added to the Zacks Rank #5 (Strong Sell) List on Nov. 28, 2025.

Alvotech (NASDAQ:ALVO) Trading Down 5.2% - Should You Sell?

Alvotech (NASDAQ:ALVO) Shares Down 5.2% - What's Next...

<ul class="summary-bullets"><li>The company said that AVT03 is approved as a biosimilar to Prolia 60 mg/mL single-use pre-filled syringe and as a biosimilar to Xgeva 70 mg/mL single-use vial.</li><li>STADA will market AVT03 as Kefdensis and Zvogra, while Dr. Reddy’s will market AVT03 as Acvybra and as Xbonzy.&nbsp;</li><li>The EC approval is based on clinical studies that demonstrated equivalent pharmacokinetics and efficacy, and comparable safety and immunogenicity to the reference product, the company said.</li></ul>Alvotech (ALVO) on Monday said that the European Commission (EC) has approved AVT03 as a biosimilar to Amgen’s Prolia and Xgeva, containing the active ingredient denosumab, and used widely to manage osteoporosis.According <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/11/24/3193283/0/en/Alvotech-Announces-Approval-of-AVT03-a-Biosimilar-to-Prolia-and-Xgeva-denosumab-in-the-European-Economic-Area.html">to</a> Alvotech, the European denosumab market is currently valued at approximately $1.2 billion across all indications. While widely used to manage osteoporosis, it is also used to prevent skeletal-related events in patients with certain cancers. Osteoporosis is a disease in which your bones become weak and are more prone to fracture due to a decrease in bone mineral density and bone mass.<h2 class="st-heading-2">EC Approval</h2>The company said that AVT03 is approved as a biosimilar to Prolia 60 mg/mL single-use pre-filled syringe for the treatment of osteoporosis and bone loss, and as a biosimilar to Xgeva 70 mg/mL single-use vial for the prevention of skeletal-related events in adults with advanced malignancies involving bone.AVT03 will be commercialised in Europe in partnerships with STADA Arzneimittel AG and Dr. Reddy’s, the company said. &nbsp;STADA will market AVT03 as Kefdensis and Zvogra, while Dr. Reddy’s will market AVT03 as Acvybra and as Xbonzy.The EC approval is based on clinical studies that demonstrated equivalent pharmacokinetics and efficacy, and comparable safety and immunogenicity to the reference product, the company said.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Shares of the company traded flat in the pre-market session at the time of writing. On Stocktwits, retail sentiment around ALVO jumped from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘extremely high’ levels.<a href="https://stocktwits.com/symbol/ALVO">ALVO stock</a> is down 61% this year and by 57% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/novo-nordisk-blockbuster-drug-fails-to-slow-alzheimers-disease-progression-in-studies/cL5bIRrREQT">Novo Nordisk’s Blockbuster Drug Fails To Slow Alzheimer’s Disease Progression In Studies</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

In this photo illustration, an Alvotech company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Alvotech’s Drug Approved In Europe As Biosimilar For Bone Disease Drug

AVT03 will be commercialised in Europe in partnerships with STADA Arzneimittel AG and Dr. Reddy’s, the company said. 

Equity

AVT03 will be commercialised in Europe in partnerships with STADA Arzneimittel AG and Dr. Reddy’s, the company said. 


Alvotech is a biotechnology company, which engages in the development and manufacture of biosimilar medicines. The firm is focusing on the development of its product candidates. It operates through the following geographical segments: Europe, North America, Asia, and Other. The company was founded by Róbert Vilhelm Wessman in 2013 and is headquartered in Luxembourg.

ALVO
Alvotech

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ALVO News

ALVOAlvotech